Peer-Administered therapy for Antenatal Depression

(P3 PAAD Trial)

Depression during pregnancy is a common complication of pregnancy and can increase the risk of preterm birth.

The purpose of this research study is to determine the effectiveness of remote (through telephone or video conferencing) therapeutic support for pregnant individuals with depression:
+ in reducing preterm birth;
+ reducing depression prior to delivery; and
+ improving anxiety symptoms.

You would be eligible to participate in this study if:
+ you have previously consented to be part of the P3 Cohort study;
+ you are currently less than 27 weeks pregnant;
+ you are 18 years of age or older; and
+ you scored >10 on the Edinburgh Postnatal Depression Scale on the P3 Cohort baseline questionnaire.

Participants who have been on a stable dose of anti-depressant medications (SSRIs) for three months or more are eligible to participate.

You are not eligible to be a participant in this study if:
+ you have a lifetime diagnosis of severe psychiatric illness (bipolar disorder, schizophrenia, borderline personality disorder, other psychoses); or
+ you are engaged in an active treatment regimen for a diagnosed mental illness (counselling or non-SSRI medications)

The Principal Investigators for this study are:
Dr. Kathleen Chaput, PhD, Department of Obstetrics and Gynecology at the University of Calgary
Dr. Lianne Tomfohr, PhD, Department of Psychology, University of British Columbia

This substudy has been approved by the University of Calgary’s Conjoint Health Research Ethics Board (REB21-1162).

If you are interested in finding out more about this research study, please contact the P3 Cohort Team at or 587-355-2036 and mention that you are interested in learning more about participating in the PAAD Trial.